Financial Performance - The company's operating revenue for the reporting period was ¥142,486,385.37, a decrease of 2.21% compared to ¥145,700,077.67 in the same period last year[24]. - Net profit attributable to shareholders was ¥23,194,022.71, down 25.89% from ¥31,298,802.56 year-on-year[24]. - The net cash flow from operating activities was -¥9,975,540.96, a decline of 235.62% compared to ¥7,355,751.21 in the previous year[24]. - Basic earnings per share decreased to ¥0.21, down 27.59% from ¥0.29 in the same period last year[24]. - Total assets at the end of the reporting period were ¥923,450,219.44, a slight increase of 0.09% from ¥922,660,005.83 at the end of the previous year[24]. - Operating costs increased by 3.49% to ¥63,450,389.26 from ¥61,310,439.67 in the previous year[61]. - Research and development expenses rose by 5.45% to ¥30,571,483.48, compared to ¥28,991,374.40 in the same period last year[61]. - The net profit after deducting non-recurring gains and losses for the current period was CNY 2,029.16 million, down 25.63% from CNY 2,728.43 million in the same period last year[183]. - The EBITDA to total debt ratio was 12.27%, down 2.70% from 14.97% in the previous year[183]. - The interest coverage ratio decreased to 136.22, down 31.50% from 198.87 in the previous year[183]. Investment and Capital Structure - The company reported a total of ¥2,902,374.04 in non-recurring gains and losses during the reporting period[30]. - The company's total share capital increased from 108,122,801 shares to 108,676,663 shares following the implementation of a stock incentive plan[22]. - The company has committed to an investment project for an annual production capacity of 3,500 sets of microbial control and detection system equipment, with a cumulative investment of 9,185.65 million yuan, achieving 65.61% of the planned investment[69]. - The project for the manufacturing base of cell therapy industrialization equipment has a total investment of 40,205 million yuan, with 9,773.82 million yuan invested by the report date[71]. - The company has approved the use of 8,886.98 million yuan of raised funds to replace self-owned funds already invested in the microbial control and detection system equipment project[71]. - The company has committed to ensuring that any share repurchases comply with relevant laws and regulations, and the repurchase price will not exceed the audited net asset value per share at the end of the previous fiscal year[121]. Research and Development - The company has established a comprehensive R&D system, including the TaiLin Research Institute and various specialized research centers, to drive innovation and product development[43]. - The company has accumulated 353 technology patents, including 30 invention patents, and has participated in the formulation of 31 national and industry standards, with 15 as the first author[51]. - Continuous investment in R&D is emphasized to ensure the development of new products and technologies that meet market demands[92]. - New product launches targeting cell therapy and biodegradation detection are underway, but market acceptance and competition may pose risks[93]. - The company has established partnerships with renowned research institutions and universities to enhance its technological capabilities and industry leadership[43]. Market and Industry Position - The company operates in the pharmaceutical equipment manufacturing industry, which is a key area encouraged by the government for innovation and industrial upgrading[47]. - The demand for life science instruments and pharmaceutical equipment is driven by advancements in cell and gene therapies, as well as new vaccine developments, leading to increased investment in the pharmaceutical sector[48]. - The company aims to expand its overseas market presence while enhancing core competitiveness through technology[93]. - The regulatory environment in areas such as food, drug safety, and environmental protection is expected to increase demand for specific products, but also intensify competition[93]. Corporate Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the board of directors and senior management[3]. - The company emphasizes the importance of risk management and has detailed potential risks and countermeasures in the report[3]. - The company plans to strengthen governance structures and internal controls to mitigate risks associated with high shareholding concentration by actual controllers[94]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, strictly fulfilling this commitment without any violations[119]. Environmental and Social Responsibility - The company has established an environmental management system to monitor and control significant environmental impacts, ensuring compliance with legal standards[111]. - The company is committed to environmental protection and resource conservation, continuously improving processes to reduce emissions[115]. - The company respects employee rights and provides necessary social security, ensuring compliance with labor laws and enhancing employee welfare[115]. - The company has not faced any administrative penalties for environmental issues during the reporting period[110]. Shareholder Information - The actual controllers, Ye Daling and Ni Weijun, hold a combined 59.01% of the company's shares, with Ye Daling also controlling an additional 7.18% indirectly through Gao De Investment[94]. - The largest shareholder, Ye Daling, holds 53.21% of the total shares, amounting to 57,824,000 shares[164]. - The total number of shareholders at the end of the reporting period was 13,351[163]. - The company has not reported any significant changes in the number of shares held by the top 10 shareholders during the reporting period[164].

浙江泰林生物技术股份有限公司独立董事 关于第三届董事会第十六次会议相关事项的独立意见 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》、《上市公司独立董事管理办法》及浙江泰林生物技术股份有限公司(以下 简称"公司")《公司章程》、《独立董事工作制度》等相关法律法规、规章制度 的有关规定，本着对公司、全体股东和投资者负责的态度，我们作为公司的独立董 事，在仔细审阅了公司第三届董事会第十六次会议相关文件后，经审慎分析，我们 认为: 独立董事签字: 杨忠智 董 明 倪 崖 一、关于 2023 年半年度募集资金存放与使用情况的专项报告的独立意见 经核查，公司 2023 年上半年募集资金的存放与使用情况符合中国证监会和深圳 证券交易所关于上市公司募集资金存放与使用的相关规定，不存在募集资金存放和 使用违规的情形。《关于 2023 年半年度募集资金存放与使用情况的专项报告》内 容真实、准确、完整，不存在虚假记载，误导性陈述或重大遗漏。 二、关于控股股东及其他关联方占用公司资金的专项说明和独立意见 经核查，我们认为报告期内公司不存在控股股东及其他关联方占用公司资金的 情况，也不存在以前年度发 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江泰林生物技术股份有限公司(以下简称"公司")第三届监事会第十三次会 议于 2023 年 8 月 18 日以电话、书面送达等形式发出通知，并于 8 月 28 日在公司会 议室召开。会议应出席监事 3 名，实际出席监事 3 名。本次会议由监事会主席倪小 璐先生召集和主持。 | 证券代码：300813 | 证券简称：泰林生物 公告编号：2023-054 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 第三届监事会第十三次会议决议的公告 司及时、真实、准确、完整地履行了相关信息披露义务。 本次会议的召开符合《公司法》、《公司章程》及有关法律、行政法规的要求，会 议合法、有效。 二、监事会会议审议情况 经与会监事审议，会议通过如下议案: 1、审议通过《2023 年半年度报告全文及其摘要》 经审核，监事会认为董事会编制和审核公司 2023 年半年度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 ...

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2023-057 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 关于 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 根据深圳证券交易所印发的《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及相关格式指引的规定，将浙江泰林生物技术 股份有限公司（以下简称"公司"）2023 年半年度募集资金存放与使用情况专 项说明如下： 一、募集资金基本情况 (一) 首次公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准浙江泰林生物技术股份有限公司首 次公开发行股票的批复》（证监许可〔2019〕2962 号）核准，公司向社会公开 发行人民币普通股（A 股）股票 1,300 万股，每股面值人民币 1 元，每股发行价 格为 18.35 元，募集资金总额为 23,855 万元，扣除本次发行费用 4,061.45 万 元后，实 际 募 集 资 金 净 额 为 19 ...

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2023-053 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 第三届董事会第十六次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2、审议通过《关于 2023 年半年度募集资金存放与使用情况的专项报告》 经审核，董事会认为，报告期内，公司募集资金的使用与管理符合《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及公司 《募集资金管理制度》等有关规定，报告期内募集资金的实际使用合法、合规， 一、董事会会议召开情况 浙江泰林生物技术股份有限公司（以下简称"公司"）第三届董事会第十六次 会议于 2023 年 8 月 18 日以电话、书面送达等形式发出通知，并于 8 月 28 日在 公司会议室以现场表决的方式召开。会议应出席董事 7 名，实际出席董事 7 名。 本次会议由董事长叶大林先生召集和主持，公司董事会秘书、监事及高管出席会 议。 本次会议的召开符合《公司法》、《公司章程》及有关法律、行 ...

上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：浙江泰林生物技术股份有限公司 单位：万元 | | 浙江泰林科 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 学技术有限 | 全资子公司 | 其他应收款 | 4540 | 900 | | 6090 | -650 | 拆借款 非经营性往来 | | | 公司 | | | | | | | | | | | 北京沃锶达 | | | | | | | | | | | 细胞技术有 | 控股子公司 | 其他应收款 | | | | | | 拆借款 非经营性往来 | | | 限公司 | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | | 总计 | - | - - | | 4540 | 9739.80 | 0 | 9582.80 | 4697 | - | | 法定代表人：叶大林 | | | | 主管会计工作负责人：叶星月 | | | | | 会计机构负责人：周文琴 | | 非经营性 ...

| 证券代码：300813 | 证券简称：泰林生物 | 公告编号：2023-051 | | --- | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | | 浙江泰林生物技术股份有限公司 关于取得专利证书及商标注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰 林生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司 （以下简称"泰林医学工程"）于近期共取得了 15 项专利证书（其中发明专利 5 项）以及 2 项商标注册证书，具体情况如下： 序号 专利名称 专利类型 申请号 授权公告日 专利权人 1 一种高效低阻超疏水纳米纤维复 合膜的制备方法 发明专利 2022103352933 2023/8/1 泰林生命科学 2 一种二氧化碳培养系统 发明专利 2019109957567 2023/6/2 泰林医学工程 3 一种过氧化氢瞬时灭菌装置及灭 菌方法 发明专利 2019114060655 2023/6/2 泰林医学工程 4 一种集菌仪结构 ...

Financial Performance - The company's revenue for Q1 2023 was ¥78,946,553.19, representing a 10.36% increase compared to ¥71,534,758.17 in the same period last year[5] - Net profit attributable to shareholders was ¥17,575,025.59, up 26.21% from ¥13,925,179.08 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 78,946,553.19, an increase of 10.8% compared to CNY 71,534,758.17 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 17,575,025.59, representing a 26.5% increase from CNY 13,925,179.08 in Q1 2022[20] - Basic earnings per share decreased by 22.22% to ¥0.21 from ¥0.27 in the same period last year[5] - Basic earnings per share for Q1 2023 were CNY 0.21, down from CNY 0.27 in Q1 2022[21] - Other income for Q1 2023 was CNY 4,217,745.67, significantly higher than CNY 105,289.96 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥17,807,115.09, a significant decline of 611.56% compared to -¥2,502,547.74 in the previous year[5] - The net cash flow from operating activities for Q1 2023 was -CNY 17,807,115.09, compared to -CNY 2,502,547.74 in Q1 2022, indicating a decline in cash flow[22] - The net cash flow from investing activities was -61,746,781.25 CNY, compared to -55,585,743.44 CNY in the previous period, indicating an increase in cash outflow[23] - Cash inflow from financing activities totaled 3,000,000.00 CNY, significantly lower than 205,800,000.00 CNY in the previous period[23] - The net cash flow from financing activities was -9,908.47 CNY, a sharp decline from 204,469,339.64 CNY in the previous period[23] - The total cash and cash equivalents at the end of the period were 202,059,043.61 CNY, down from 319,191,845.37 CNY in the previous period[23] - The net increase in cash and cash equivalents was -79,563,804.81 CNY, contrasting with an increase of 146,371,343.00 CNY in the previous period[23] - The company reported a total cash outflow from investing activities of 81,768,109.55 CNY, compared to 75,645,743.44 CNY in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥922,917,372.63, a slight increase of 0.03% from ¥922,660,005.83 at the end of the previous year[5] - The total assets of Zhejiang Tailin Biotechnology Co., Ltd. as of March 31, 2023, amounted to CNY 922,917,372.63, showing a slight increase from CNY 922,660,005.83 at the beginning of the year[16] - The company's cash and cash equivalents decreased to CNY 548,796,995.73 from CNY 577,153,986.25, reflecting a decline of approximately 4.5%[16] - Accounts receivable increased to CNY 54,583,843.48 from CNY 42,578,297.85, representing a growth of about 28.3%[16] - Inventory decreased to CNY 107,337,687.08 from CNY 111,201,218.36, indicating a reduction of approximately 3.4%[16] - Current liabilities decreased to CNY 105,402,583.19 from CNY 129,326,260.25, a decline of about 18.5%[17] - The total liabilities decreased to CNY 254,205,720.40 from CNY 275,205,185.78, reflecting a decrease of approximately 7.6%[17] - The company's total equity attributable to shareholders increased to CNY 668,711,652.23 from CNY 647,454,820.05 year-over-year[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,781[10] - The largest shareholder, Ye Daling, holds 53.48% of the shares, totaling 44,480,000 shares[10] - The company has a significant shareholder, Ye Daling, holding 11,120,000 shares, which is 5.83% of the total shares[11] - The company reported a total of 56,644,160 shares under lock-up agreements, with 18,379,640 shares released during the period[14] Research and Development - The company plans to maintain its focus on research and development of new products and technologies to enhance market competitiveness[12] - Research and development expenses for Q1 2023 were CNY 13,945,439.84, slightly up from CNY 13,701,030.39 in the previous year[19] Other Information - The company received government subsidies amounting to ¥1,835,702.90 during the reporting period[6] - The company did not conduct an audit for the first quarter report[24] - The company is exploring opportunities for market expansion and potential mergers and acquisitions to drive growth[12] - The company reported a decrease in financial asset impairment losses to -CNY 176,430.03 from -CNY 323,417.79 in the previous year[20]

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 编号：2023003 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 4 月 13 日 (周四) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、泰林生物 董事长、总经理叶大林 | | 员姓名 | 2、泰林生物 董事会秘书兼财务总监叶星月 | | | 3、独立董事杨忠智 | | | 4、保荐代表人严绍东 | | | 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、公司最有核心竞争力的产品是什么 | | | 答：尊敬的投资者，您好！公司 ...

Financial Performance - The company's operating revenue for 2022 was CNY 373,878,114.24, representing a 32.00% increase compared to CNY 283,248,491.21 in 2021[19]. - The net profit attributable to shareholders for 2022 was CNY 79,686,202.54, a 25.43% increase from CNY 63,529,851.10 in 2021[19]. - The cash flow from operating activities for 2022 was CNY 89,385,619.71, showing a significant increase of 148.56% from CNY 35,961,769.59 in 2021[19]. - The total assets at the end of 2022 amounted to CNY 922,660,005.83, a 40.68% increase from CNY 655,871,410.07 at the end of 2021[19]. - The company reported a basic earnings per share of CNY 0.96 for 2022, up 26.32% from CNY 0.76 in 2021[19]. - The company achieved operating revenue of ¥373,878,114.24, a year-on-year increase of 32.00%, and a net profit attributable to shareholders of ¥79,686,202.54, up 25.43% compared to the previous year[59]. - Total assets reached ¥922,660,005.83, reflecting a growth of 40.68% year-on-year[59]. - Revenue from the pharmaceutical industry amounted to ¥344,999,759.36, accounting for 92.28% of total revenue, with a year-on-year growth of 36.02%[79]. - The gross profit margin for the pharmaceutical industry was 50.34%, a decrease of 8.46% compared to the previous year[82]. Research and Development - The company is actively engaged in research and development of new technologies, including vaporized hydrogen peroxide sterilization systems[12]. - The company is actively engaged in the research and development of life science instruments and new biopharmaceutical equipment, with a focus on cell therapy-related equipment[31]. - The company has established a multi-level R&D system, including the TaiLin Research Institute and various specialized research centers, to enhance its continuous R&D capabilities[45]. - The company invests over 10% of its sales revenue annually into technology research and new product development, resulting in a total of 334 technology patents, including 28 invention patents[50]. - The company has 55 ongoing research and development projects, indicating a strong focus on innovation and technology advancement[108]. - The company has launched products targeting the cell therapy industry and biodegradation testing, but faces challenges in market acceptance and competition[132]. Product Development and Market Strategy - The company aims to expand its market presence through strategic partnerships and acquisitions in the biotechnology sector[12]. - The company is focusing on expanding its product line to include a variety of specifications for different customer needs in the biological product and cell culture industries[92]. - The company is focusing on product development in precision medicine and medical devices to create new business growth points[126]. - The company plans to enhance its international competitiveness by improving product design and user experience through collaboration with professional design teams[94]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[197]. - New product lines are anticipated to launch in Q3 2023, expected to contribute an additional 200 million RMB in revenue[198]. Corporate Governance and Management - The company maintains a strong commitment to corporate governance and transparency in its operations[145]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[139]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[141]. - The company has implemented a robust internal audit system to ensure the authenticity and completeness of financial information[140]. - The company has established a risk management organization comprising the audit committee and internal audit department to oversee internal controls[181]. - The company has a transparent and open process for appointing senior management personnel[141]. Environmental and Social Responsibility - The company has committed to strict compliance with environmental regulations, continuously improving processes to reduce energy consumption and pollutant emissions[191]. - The company has developed a comprehensive environmental management system to monitor and control significant environmental impacts[188]. - The company has a focus on protecting employee rights, providing a safe working environment, and ensuring compliance with labor laws[190]. - The company has established a monitoring program to ensure compliance with environmental performance targets and legal standards[188]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[187]. Future Outlook and Strategic Initiatives - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[199]. - A strategic acquisition of a smaller biotech firm is expected to be finalized by Q2 2023, which will enhance the company's product portfolio[199]. - The company plans to implement its first stock incentive plan post-IPO and enhance performance assessment for core employees to boost motivation[126]. - The company is implementing cost-cutting measures aimed at reducing operational expenses by 15% over the next year[199]. - The company plans to repurchase shares using its own funds, with a total amount not exceeding the funds raised from its latest public offering of A-shares[200].